Haw. Code R. § 16-92-2
As used in this chapter or in chapter 459, HRS:
"Adverse effects" means any undesired side effects brought on by the use of diagnostic or therapeutic pharmaceutical agents.
"Board" means the board of examiners in optometry.
"Department" means the department of commerce and consumer affairs.
"Diagnostic pharmaceutical agents" or "DPAs" means topically applied pharmaceutical agents known as anesthetics, cycloplegics, and mydriatics.
"Laboratory tests" means any diagnostic evaluation performed by a licensed medical laboratory pertaining to ocular conditions.
"NBEO" means the National Board of Examiners in Optometry.
"Non-invasive diagnostic procedures" means any procedure used for the purpose of diagnosing ocular diseases or disorders, excluding surgery or injection; provided that a therapeutically certified optometrist may administer injectable agents for anaphylaxis only.
"Spectacle prescription" means an order or formula issued by a practitioner licensed by the State or authorized by the laws of the State to prescribe prescription ophthalmic lenses, setting forth refractive powers for the manufacturing of any lens which has a spherical, cylindrical prismatic power or value or any combination thereof. A spectacle lens prescription expiration date shall be determined by the professional judgment of the licensed practitioner.
"Therapeutic pharmaceutical agents" or "TPAs" means ingested oral agents, or topical solutions, suspensions, and ointments applied to the surface of the eye or adjoining tissues. Therapeutically certified optometrists are authorized to use and prescribe therapeutic pharmaceutical agents specifically formulated for ophthalmic use, as approved by the Food and Drug Administration, and with the exception of any controlled substance as defined in chapter 329, HRS (Uniform Controlled Substance Act).
Haw. Code R. § 16-92-2